CIK 0001358403
BLCM BELLICUM PHARMACEUTICALS, INC
Insider trading from SEC Form 4. Last filing Nov 24, 2023.
In brief
BELLICUM PHARMACEUTICALS, INC (BLCM) has 8 SEC Form 4 filings on file from 6 insiders, the latest filed on Nov 24, 2023. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at BELLICUM PHARMACEUTICALS, INC, scored.
Transactions
Every row filed, 11 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 22, 2023 | Baker Bros. Advisors LP owner | XIn-the-money exercise Common Stockindirect: See Footnotes | +174,742 | $0.00 | $17 | 196,654 | Nov 24, 2023 |
| Nov 22, 2023 | Baker Bros. Advisors LP owner | XIn-the-money exercise Common Stockindirect: See Footnotes | +1,941,607 | $0.00 | $194 | 2,168,818 | Nov 24, 2023 |
| Nov 22, 2023 | Baker Bros. Advisors LP owner | XIn-the-money exercise Warrants (right to buy)derivativeindirect: See Footnotes | -174,742 | $0.00 | $0 | 1,287,987 | Nov 24, 2023 |
| Nov 22, 2023 | Baker Bros. Advisors LP owner | XIn-the-money exercise Warrants (right to buy)derivativeindirect: See Footnotes | -1,941,607 | $0.00 | $0 | 14,217,844 | Nov 24, 2023 |
| Jan 3, 2023 | Reid M Huber director | MOption exercise Common Stock | +80,968 | $0.00 | $0 | 146,951 | Jan 20, 2023 |
| Jan 3, 2023 | Judith Klimovsky V director | MOption exercise Common Stock | +60,414 | $0.00 | $0 | 110,098 | Jan 5, 2023 |
| Jan 3, 2023 | Jon P Stonehouse director | MOption exercise Common Stock | +121,452 | $0.00 | $0 | 204,086 | Jan 5, 2023 |
| Jan 3, 2023 | Reid M Huber director | MOption exercise Common Stock | +87,196 | $0.00 | $0 | 153,179 | Jan 5, 2023 |
| Jan 3, 2023 | Stephen Davis director | MOption exercise Common Stock | +74,739 | $0.00 | $0 | 136,854 | Jan 5, 2023 |
| Jan 3, 2023 | James M Daly director | MOption exercise Common Stock | +60,414 | $0.00 | $0 | 109,873 | Jan 5, 2023 |
| Sep 1, 2022 | Jon P Stonehouse director | MOption exercise Common Stock | +60,580 | $0.00 | $0 | 82,634 | Jan 4, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Baker Bros. Advisors LPdirector, owner, other
- Stephen Davisceo, officer, director
- James M Dalydirector
- Reid M Huberdirector
- Judith Klimovsky Vdirector
- Jon P Stonehouseceo, president, officer, director
Questions about BLCM
Answered from the filings on this page, as of the latest one.
Are insiders buying BLCM?
No. In the last 90 days no insider at BELLICUM PHARMACEUTICALS, INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade BLCM on the open market?
No open-market trade has been scored at BELLICUM PHARMACEUTICALS, INC. The latest Form 4 on file was filed on Nov 24, 2023 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at BELLICUM PHARMACEUTICALS, INC?
6 people have filed a Form 4 at BELLICUM PHARMACEUTICALS, INC, among them Baker Bros. Advisors LP (director and 10% owner), Stephen Davis (CEO and director), James M Daly (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.